emagine Development

What is comparability testing and why is it important?

Comparability testing helps sponsors evaluate whether product quality attributes remain consistent following manufacturing, process, formulation, or analytical changes.

When should bioanalytical assay development begin?

Assay development must begin during later discovery and lead molecule optimization, long before the first human is dosed. Assays should begin as early as possible in preclinical or early clinical stages to ensure methods are optimized, validated, and ready to support critical study timelines preventing delays in regulatory submissions and clinical starts.

What is immunogenicity testing and when is it required?

Immunogenicity testing is the bioanalytical assessment of a patient’s immune response to a therapeutic product. Specifically testing that evaluates a patient’s anti-drug antibody (ADA) and neutralizing antibodies (NAbs) responses to biologic therapies. It is required continuously throughout clinical development to assess potential impacts on safety, efficacy, and pharmacokinetics.

Can BioAgilytix support complex modalities like ADCs, cell and gene therapies, or RNA therapeutics?

Yes. BioAgilytix has extensive experience supporting complex and emerging modalities, including ADCs, cell and gene therapies, oligonucleotides, and mRNA, with tailored bioanalytical and CMC analytical strategies.

How does BioAgilytix ensure consistent bioanalytical data across global studies?

Through harmonized processes, standardized platforms, and integrated quality systems across all global laboratories, ensuring consistent, high-quality data regardless of study location. Contact Us